Vildagliptin (Galvus®) 50 mg tablets

All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000878
Authors' recommendations: Vildagliptin (Galvus®) 50 mg tablets are recommended as an option for use within NHS Wales for the treatment of type 2 diabetes in patients with moderate or severe renal impairment.
Project Status: Completed
Year Published: 2012
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Wales, United Kingdom
MeSH Terms
  • Dipeptidyl-Peptidase IV Inhibitors
  • Diabetes Mellitus, Type 2
  • Blood Glucose
  • Pyrrolidines
  • Nitriles
  • Adamantane
Organisation Name: All Wales Medicines Strategy Group
Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
Contact Email:
Copyright: AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.